Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Moximed Names Christopher Gleason as Chief Exec - Orthopedic Design & Technology

What are you searching for?

Sign in
OEM News, People News

Moximed Names Christopher Gleason as Chief Exec

Most recently, Gleason was VP of sales at Relievant, which was acquired by Boston Scientific for $850 million late last year.

Author Image

By: Sam Brusco

Associate Editor

Moximed has appointed Christopher Gleason as its new president and CEO.
 
Most recently, Gleason was VP of sales at Relievant, which was acquired by Boston Scientific for $850 million late last year. He also previously served as VP of interventional urology sales at Teleflex and other sales leadership positions at NeoTract before it was acquired by Teleflex in 2017.
 
Gleason was also in leadership roles at Xenex Healthcare and Acclarent at Johnson & Johnson.
 
“It is an honor to join Moximed as we expand access of the MISHA Knee System to the many knee OA patients in the U.S. who may benefit,” said Gleason. “I have spoken to a number of patients, and I’m inspired by the amazing stories of how the MISHA Knee System has positively impacted their lives. We have a talented team who is relentlessly dedicated to advancing patient care, and I look forward to helping Moximed realize its tremendous potential.”
 
Moximed announced it had completed its first commercial cases with the MISHA implantable shock absorber for patients with medial knee osteoarthritis (OA) last September. The Fremont, Calif.-based company also welcomed new chief financial and strategy officer James Leech earlier this year.
 
“I’m thrilled to have Chris take the leadership role at Moximed and drive the expansion phase of the company,” said Moximed co-founder and chief technology officer Anton Clifford, Ph.D. “We’re seeing tremendous clinical results from commercial use of the MISHA Knee System, and it’s the perfect time for Chris to broaden our commercial reach and enable greater product access for the benefit of patients.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Add Orthopedic Design & Technology as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters

Topics